⌕
BridgeBio Pharma · BBIO · Nasdaq
Tenet 43 · Weak
Compare
$76.80−0.72%At closeTenet 43 · Weak
$76.80−0.56 (−0.72%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

BridgeBio Pharma (BBIO) Stock

BridgeBio Pharma (BBIO) closed at $76.80 on Nov 17, 2026; its Tenet Score is 43 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

32 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$76.80
Nov 17, 2026
Market cap
$15.1B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
62.50 – 93.42
low → high · as of close, Nov 16, 2026
Tenet Score
43/100
Weak · 340 Healthcare peers

Industry: Health Services

BridgeBio Pharma Inc scores 43/100. Weak. Quality is the soft spot versus 340 Healthcare peers. Insufficient inputs: Tenet 43 is built from 3 of 4 pillars, from 40% of its inputs. The pillars showing a dash had no data.

Tenet Score · vs sector

n=340
43/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
—
Quality
33
Health
40
Growth
57

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Value omitted — no data yet.
Value—QualityDHealthDGrowthCMomentumD
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
—
Not meaningful: shareholders' equity is zero or negative.
P/S
15.9×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
—
Not meaningful: shareholders' equity is zero or negative.
Operating margin
−104.2%
fiscal 2025, before interest and tax
Net margin
−59.8%
TTM through Sep 30, 2026
Current ratio
2.09
Sep 30, 2026 balance sheet
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About BridgeBio Pharma Inc

BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage developmen…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 123 US ETFs · top wrappers by weightSee all ETFs holding BBIO →

Similar-sized companies in Health Services

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is BridgeBio Pharma in?

BridgeBio Pharma is in the Healthcare sector and the Health Services industry.

What is BridgeBio Pharma's Tenet Score?

BridgeBio Pharma's Tenet Score is 43 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.